GP
PTLA

Girard Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Girard Partners’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-545
Closed -$14K – 924
2018
Q3 		$14K Buy
+545
New +$17.8K ﹤0.01% 667

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Girard Partners's PTLA Position: Q4 2018 in Review

Girard Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 545 shares — an estimated $14K sold.

Girard Partners first reported a position in PTLA in Q3 2018 and held it in 1 quarter. The position peaked at $14K in Q3 2018. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

  • Girard Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Girard Partners sold 545 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $14K.
  • Girard Partners first reported a position in Portola Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Girard Partners's Portola Pharmaceuticals, Inc. position peaked at $14K in Q3 2018.
  • 181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.